Search - tctmd.com

Displaying 1 - 20 of 202

Sort: Relevancy | Date

News Industry News

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

November 21, 2016

News Industry News

Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

September 12, 2016

News Industry News

BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

June 27, 2016

News Industry News

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

June 17, 2016

News Industry News

Secondary Analysis of EXAMINE Trial Finds Highest Risk of Cardiovascular Death for Patients Previously Hospitalized with Heart Failure

June 13, 2016

News Industry News

DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

April 26, 2016

News Industry News

Stroke Prevention: BIOTRONIK Announces FDA Approval of BioMonitor 2 Insertable Cardiac Monitor

April 12, 2016

News Industry News

New Research Shows Abbott's High Sensitive Troponin Test First To Measure Impact Of Mental Stress On The Heart

April 04, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Industry News

STENTYS: Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention

February 28, 2016

News Industry News

Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack

February 18, 2016

News Industry News

TherOx Enrolls First Patient in Study of Next-Generation Supersaturated Oxygen Therapy for AMI

February 17, 2016

News Industry News

XENIOS® AG receives CE mark for its i-cor® Synchronized Cardiac Assist System

November 24, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

TherOx Receives FDA IDE Approval for Study of Next-Generation Supersaturated Oxygen Therapy for AMI

November 04, 2015

News Industry News

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

November 02, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Ventrix Initiates Clinical Trial of VentriGel™

September 17, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

Advertisement

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

BioVentrix Receives CE Marking Certification for Revivent TC™, the First Minimally Invasive Heart Failure Treatment to Restore the Left Ventricle

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

Secondary Analysis of EXAMINE Trial Finds Highest Risk of Cardiovascular Death for Patients Previously Hospitalized with Heart Failure

DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

Stroke Prevention: BIOTRONIK Announces FDA Approval of BioMonitor 2 Insertable Cardiac Monitor

New Research Shows Abbott's High Sensitive Troponin Test First To Measure Impact Of Mental Stress On The Heart

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

STENTYS: Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention

Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack

TherOx Enrolls First Patient in Study of Next-Generation Supersaturated Oxygen Therapy for AMI

XENIOS® AG receives CE mark for its i-cor® Synchronized Cardiac Assist System

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

TherOx Receives FDA IDE Approval for Study of Next-Generation Supersaturated Oxygen Therapy for AMI

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Ventrix Initiates Clinical Trial of VentriGel™

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content